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tified mutations in NKX2.5 in four families with ASD and atrioventricular conduction disturbance, 18 whereas Garg et al have identified mutations in GATA4 in 2 families with ASD and VSD. 19 However, the genetic basis of most types of CHDs is yet to be determined because the overwhelming majority of CHDs are non-syndromic with no segregation in Mendelian ratios.
Recently, we identified 2 mutations in GATA6 by screening DNA from 21 non-syndromic patients with persistent truncus arteriosus (PTA), which is the most severe outflow tract (OFT) defect. 20 We also demonstrated a molecular basis for the pathogenesis of PTA, whereby mutations in GATA6 resulted in a disturbance of direct regulation of semaphorin 3C (SEMA3C) and plexin A2 (PLXNA2), which mediate essential neurovascular signaling in the development of the OFT. 20 To further explore the genetic causes of non-syndromic and non-familial CHDs, we undertook a genetic analysis of selected essential cardiac transcription factors, focusing on lesions involving the OFT. OFT defects constitute approximately 30% of CHDs 21 and are often difficult to repair surgically because of complex morphological abnormalities, resulting in an unfavorable prognosis. In the present study, we report our findings in 256 nonsyndromic patients with OFT defects.
Methods
A detailed description of the methodology used is available as online supplemental information for this paper (Data S1).
Mutation Analysis and Clinical Evaluation of Patients
The establishment of a genomic bank with different cell lines and the extraction of genomic DNA samples have been described previously. 22 All exons and flanking introns of NKX2.5, GATA4, GATA6, MEF2C, and ISL1 were amplified by polymerase chain reaction (PCR) and were sequenced using direct, bidirectional sequencing (Data S1). The mutations identified were subsequently confirmed using original genomic DNA extracted from the patients' peripheral blood leukocytes. Primer sequences are given in Table S2 . In all, 256 samples were collected from patients with CHDs involving OFT defects. Phenotypic data for the affected individuals and their family members were obtained from detailed clinical evaluations based on echocardiography, cardiac catheterization, and/or surgical findings. Genomic samples from available family members, 206 healthy Japanese volunteers with no CHDs (controls), and 294 samples of control genomic DNA (BioChain, Hayward, CA, USA) were analyzed using the same protocol. This investigation conformed with the principles outlined in the Declaration of Helsinki, and the clinical evaluations and genetic studies of the patients and their families were approved by the Internal Ethics Committee of Tokyo Women's Medical University and were undertaken only after the patients and their family members had provided informed consent.
Plasmid Construction and Site-Directed Mutagenesis
Site-directed mutagenesis was performed using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. GATA6-pcDNA3.1, 20 NKX2.5-pcDNA3.1, GATA4-pcDNA3.1 or Mef2c-pcDNA were used for mutagenesis. Mef2c-pcDNA was kindly provided by Dr Brian Black (Cardiovascular Research Institute, University of California, San Francisco, CA, USA). Mouse Mef2c wild-type (WT) and A103V mutant cDNA were subcloned into a pCS2+ plasmid. 23 All vectors constructed were verified by sequencing.
Luciferase Assay
HeLa cells were transfected using Lipofectamine LTX and Plus reagent (Invitrogen, Carlsbad, CA, USA) with 400 ng reporter vector, 800 ng expression vectors, and 0.25 ng pSV-Rluc internal control vector, as described previously. 20 Luciferase activity was measured 36 h after transient transfection by using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Experiments were repeated at least 3 times.
Co-Immunoprecipitation Assays
COS-1 cells were transiently transfected with lipofectamine LTX (Invitrogen), collected after 48 h in lysis buffer (Tris-buffered saline (TBS), 0.4% Nonidet P-40 (NP-40), and EDTAfree complete protease inhibitor cocktail; Roche Diagnostics, Basel, Switzerland), incubated with monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, USA) and Dynabeads protein G beads (Invitrogen), immunoblotted with monoclonal anti-GATA6 (R&D systems, Minneapolis, MN, USA) or monoclonal anti-FLAG M2 antibodies, and detected by western blotting.
Overexpression of Mef2c mRNA in Medaka Fish
The plasmid mouse Mef2c WT or A103V mutant-pCS2+ was digested with Not I, and RNA samples of the Mef2c with polyA were prepared using the mMessage mMachine Kit (Invitrogen) for injections. Medaka embryos were fertilized in vitro and injected at the 1-cell stage (215 eggs) as previously described. 24 Pressure was adjusted to inject approximately 1 nl at a concentration of 0.2 μg/μl. Injected embryos were transfered into heat type of container where they were held at 28.5 degrees celsius. Embryos were observed, scored daily, and investigated for cardiac phenotypes at 5 days post-fertilization.
Statistical Analysis
For luciferase assays, all experiments were performed at least in triplicate and data are reported as normalized relative light units (fold activation) together with the SEM. For promoter activity assays, all experiments were performed at least in triplicate and data are reported as the ratio of normalized relative light units for coexpression with NKX2.5, GATA4, GATA6, or Mef2c to that with mock (pcDNA3.1). In all Figures, error bars indicate the SEM. Data were analyzed by 2-tailed unpaired t-test or chi-square test. P≤0.05 was considered significant. For non-synonymous GATA4 and GATA6 nucleotide changes found in patients and controls, frequencies were compared between patients and controls by chi-square test. P≤0.05 was considered significant.
Results

Novel Sequence Variants of Genes Encoding Cardiac Transcription Factors Identified in Patients With Non-Syndromic CHDs
In our genetic analysis of selected essential cardiac transcription factors (NKX2.5, GATA4, GATA6, MEF2C, and ISL1) in 256 patients with non-syndromic OFT defects, including 125 with tetralogy of Fallot (TOF), 84 with pulmonary atresia with VSD, 23 with double outlet the right ventricle, and 24 with PTA, we identified 5 new sequence variants in 6 individuals (6/256; 2.3%). These variants included an NKX2.5 variant (A6V), 2 GATA4 variants (T330R and S339R), a GATA6 variant (E142K), and a MEF2C variant (A103V; Figure 1 ) that were not found in the 500 normal controls without CHDs, suggesting that these variants are potentially involved in the etiol-Genetic Analysis in Congenital Heart Defects ogy of OFT defects. The results of the genetic analyses and the associated phenotypes are summarized in Table 1 . As indicated in Table 1 , the GATA6 variant E142K was found in 2 unrelated patients with OFT defects whose phenotypes were somewhat variable. We also identified non-synonymous variations in the coding regions of GATA4 and GATA6 in both patients and controls ( Table 2) , as well as numerous known sequence polymorphisms in all genes, although none of these non-synonymous sequence variants showed significant difference in the frequency between patients and controls. We did not find any new sequence variants of ISL1 in our patient group. 
Functional Analyses of Cardiac Transcription Factors With the Identified Sequence Variations
To examine the clinical relevance of the identified sequence variants to non-syndromic OFT defects, luciferase assays were performed to evaluate the transcriptional activity of each factor exhibiting a sequence variation. First, we analyzed basal transcription activities using the common cardiac-specific promoter NPPA. The NKX2.5 variant A6V exhibited a 50% decrease in transcription activity compared with the WT protein (Figure 2A ; P=0.0066, 2-tailed unpaired t-test; n=3). In addition, this variant exhibited a significant decrease in synergistic effects when it was cotransfected with GATA4 compared with WT NKX2.5 cotransfected with GATA4 (Figure 2A ; P=0.011, 2-tailed unpaired t-test; n=3).
The 2 GATA4 variants T330R and S339R exhibited significant decreases in synergistic effects on the NPPA promoter compared with WT GATA4 when they were cotransfected with NKX2.5 ( Figure 2B ; P=0.015 and P=0.026, respectively 2-tailed unpaired t-test; n=3), although, alone, neither variant exhibited any significant decrease in transcription activity on the NPPA promoter. The GATA4 variant S339R also exhibited a significant decrease in its synergistic effect with GATA6 ( Figure 2B ; P=0.044, 2-tailed unpaired t-test; n=3), whereas the GATA4 variant T330R did not.
The GATA6 variant E142K exhibited significantly decreased transcriptional activity on the NPPA promoter ( Figure 2C ; P=0.0045, 2-tailed unpaired t-test; n=3). Furthermore, the GATA6 variant E142K exhibited significantly decreased synergistic activity with GATA4 on the NPPA promoter compared with WT GATA6 (Figure 2C ; P=0.0010, 2-tailed unpaired ttest; n=3). In addition to synergistic effects between GATA6 and GATA4 on the NPPA promoter, we also found synergistic effects for GATA6 with TBX5 on the NPPA promoter (Figure 2C ; P=0.034 for GATA6 WT with TBX5 v. GATA6 alone; P=0.031 for TBX5 alone, 2-tailed unpaired t-test; n=3). Furthermore, results from the co-immunoprecipitation assay revealed that the GATA6 protein was able to physically associate with the TBX5 protein ( Figure 2D ; WT), suggesting that the strong synergistic effect on the expression of NPPA was due to a direct interaction between GATA6 and TBX5. The GATA6 variant E142K exhibited significantly decreased synergistic activity with TBX5 on the NPPA promoter compared with WT GATA6 (Figure 2C ; P=0.00092, 2-tailed unpaired t-test; n=3), although the interaction between the GATA6 variant E142K and TBX5 was unaffected ( Figure 2D; E142K) . Moreover, compared with WT GATA6, the GATA6 variant E142K exhibited significantly decreased transcription activity on the SEMA3C promoter ( Figure 2E ; P=0.029, 2-tailed unpaired t-test; n=3) and the WNT2 promoter (Figure 2F ; P=0.040, 2-tailed unpaired t-test; n=3), both of which are downstream targets of GATA6.
Although no disease-associated mutation in MEF2C has been reported to date, we identified a non-synonymous MEF2C sequence variant (A103V) in the present study. A recent animal study reported that Mef2c directly regulates Smyd1, which is essential for early cardiomyocyte differentiation during development of the OFT. 25 To investigate whether the MEF2C variant A103V results in a disruption of Smyd1 regulation, we used a Smyd1 promoter that included an Mef2c-dependent consensus sequence 25 ( Figure 2G ) in our luciferase assay. The results suggest that the MEF2C variant A103V has a significant gain-of-function activity on the Smyd1 promoter compared with WT MEF2C (Figure 2H ; P=0.040, 2-tailed unpaired t-test; n=3). The results of all functional analyses are summarized in Table 1 .
Abnormal Heart Development in Medaka Fish With Overexpression of Mef2c
MEF2C is a highly conserved protein across species (Figure 3A ) and alanine 103 is well conserved (Figure 1D) . In order to assess the gain-of-function of MEF2C A103V variant protein during heart development in vivo, we used a fish system. Overexpression of Mef2c WT or A103V protein in medaka by mRNA injections showed a range of abnormal cardiac development (Figures 3B-E ; Movies S1,S2). Approximately 25% of embryos injected with WT Mef2c and 40% of embryos injected with A103V variant Mef2c developed cardiac defects ranging from disorganized cardiac chamber formation in the straight heart tube to ectopic beating tissues with no formation of the heart tube, suggesting that overexpression of Mef2c may disturb early cardiac development. Consistent with A103V variant having a gain-of-function effect on the transcriptional activity of Mef2c, abnormal cardiac development was observed more frequently in transgenic medaka embryos injected with the variant Mef2c than those with the WT (Figure 3F ; P=0.015, chi-square test).
Discussion
Herein we report on the identification and characterization of multiple sequence variants of the transcription factors, that are essential for cardiac development, in non-syndromic patients with cardiac OFT defects. Each variant exhibited changes, to varying degrees, in the transcriptional activity of its protein products on downstream target genes involved in heart development. The results suggest that the sequence variations identified in NKX2.5, GATA4, GATA6, and MEF2C in the present study are likely to be involved in some aspect of the etiology of OFT defects, accounting for approximately 2.3% of cases of non-syndromic OFT defects (6 cases of 256 patients in the present series). These findings suggest that a subset of CHDs The heart morphogenesis is shown in illustration to see the phenotype of cardiac development in each embryo. In control embryos without injection, atrium (a) and ventricle (v) are segmented in the looped heart tube (B). On the other hand, cardiac formation was disturbed in medaka with Mef2c wild-type (WT; C) or A103V mRNA injection (D,E). h, premature heart. Scale bars=500 μm. (F) The frequency of abnormal cardiac phenotype in medaka embryos injected with Mef2c WT and A103V mutant. Numbers of observed embryos are indicated in white. Medakas injected with Mef2c A103V mRNA showed abnormal cardiac phenotype more frequent than those injected with Mef2c WT (P=0.015, chi-square test). Genetic Analysis in Congenital Heart Defects may be caused by disruption of cardiac transcription factor regulation. The approach we used in the present study may prove useful in identifying new genetic causes and exploring unknown molecular mechanisms underlying non-syndromic and non-familial CHDs, despite the known difficulties in determining the genetic basis of most such cases of CHDs.
A previous study has indicated that mutations in the homeodomain of NKX2.5 are likely to cause ASD, whereas mutations located outside the homeodomain may be associated with OFT defects. 26 Benson et al first identified mutations in the N-terminal region of NKX2.5 in patients with TOF, and this region may be a hot spot for mutations responsible for TOF 27 ( Figure 4A) . Consistent with this notion, in the present study we identified the novel sequence variant A6V in the N-terminal region of NKX2.5 in a patient with TOF. It is known that the N-terminal region is required for NKX2.5 activity essential for cardiomyogenesis. 28 The NKX2.5 variant A6V exhibited significantly decreased transcriptional activity, which likely resulted in TOF in our patient.
Mutations in GATA4 are known to cause intracardiac septal defects, probably as a result of disruptions to interactions with TBX5. 19 Although only a few reports have demonstrated an association between GATA4 mutations and OFT defects, 29 in the present study we identified 2 novel GATA4 sequence variants in patients with OFT defects (Figure 4B ). Both GATA4 variants (T330R and S339R) were located in a common basic region of the GATA transcriptional factors and both variants resulted in a disruption of the synergistic activity between GATA4 and NKX2.5 or GATA6, although the correlation between the genotype and phenotype was unclear. It is of note that each variant alone did not exhibit any significant decrease in transcription activity. It has been reported that reciprocal regulation between GATA4 and NKX2.5, as well as a synergistic activity between them, is essential for several cardiacspecific genes. 30-34 Other studies have indicated that GATA4 plays a role in cardiovascular development in collaboration with GATA6. 9,35,36 Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation, resulting in acardia in mice. 37 GATA4 and GATA6 regulate MEF2C by binding directly to its enhancer and via calcium-dependent pathways; 38,39 in turn, MEF2C plays a role in the differentiation of the OFT myocardium and vascular smooth muscle cells from their progenitor pool (ie, the second heart field). 10 These observations suggest that GATA4 and GATA6 may function redundantly as well as cooperatively in multiple steps of cardiovascular development, ranging from the differentiation of cardiac progenitor cells to the development of the OFT. On the basis of the results obtained in the present study, we believe that a decrease in the synergistic activity of GATA4 with NKX2.5 or GATA6 may result in some type of OFT defect.
The novel GATA6 variant E142K exhibited significantly decreased transcriptional activity, as well as decreased synergistic activity with other cardiac transcription factors, making this variant a strong candidate for a subset of OFT defects. Since our initial report of the first mutations in GATA6 associated with OFT defects, 20 a further 3 mutations have been reported, with 2 of them associated with OFT defects 40,41 ( Figure 4C ). These findings indicate that mutations in GATA6 may be mainly associated with OFT defects, probably as a result of the dysregulation of the SEMA3C -PLXNA2 pathway. 20 The present study revealed that GATA6 binds directly to TBX5, which is the first demonstration of a direct physical interaction between GATA6 and TBX5 leading to synergistic activity. The GATA6 variant E142K exhibited decreased synergistic activity with TBX5; however, its direct interaction with TBX5 was not altered. These results suggest that TBX5 binds to GATA6 normally via the zinc finger domain, like other cofactors, but the sequence variation E142K in the N-terminal domain of GATA6 changes transactivation on the target gene independent of binding to TBX5.
The present study also reports the first sequence variation in MEF2C associated with CHDs ( Figure 4D) . MEF2C is essential for the development of the right ventricle and the OFT interacting with NKX2.5. 42 Loss of Mef2c in mice results in hypoplasia of the right ventricle and the OFT. 10,11 Furthermore, Mef2c is thought to have an essential role in ventricular cardiomyocyte differentiation, 43 and, recently it was reported that a transduction of Mef2c together with Gata4 and Tbx5 rapidly and efficiently reprogrammed postnatal fibroblasts directly into differentiated cardiomyocyte-like cells. 44 Intriguingly, Mef2c overexpression assay using fish in this current study showed defects of cardiac development, including disorganized cardiac chamber formation and ectopic cardiomyocyte differentiation. These findings indicate that the level of transcriptional activity of Mef2c should be critically controlled for normal cardiac development. In our study, the A103V variant of Mef2c identified in a patient with OFT defect showed gainof-function in transcriptional activity on the promoter of its downstream target, Smyd1, which is essential for early cardiomyocyte differentiation of development of the right ventricle and OFT. 25 Consistently, abnormal cardiac development was observed more frequently in transgenic fish embryos overexpressing the A103V variant of Mef2c than in those with the WT Mef2c. Taken together, our findings suggest that the gene mutation causing the A103V variation of MEF2C is likely to be implicated in the OFT defect as a result of altered transcriptional activity of MEF2C.
Of note, we did not identify any sequence variants in ISL1. During development, Isl1 is expressed in the splanchnic mesoderm comprising the second heart field, which gives rise to the OFT, right ventricle, and most parts of the atria, but is downregulated in the heart proper. 45 In contrast, Nkx2.5, Gata4, Gata6, and Mef2c are expressed continuously in the heart during development. 12- 14 One could speculate that this may be why no CHD-associated sequence variant was found in ISL1 in the present study, although this finding does not rule out the possibility that ISL1 is responsible for some type of OFT defect in humans. Clearly, in the present study we did not attempt to incorporate the effects of all factors relevant to heart development. Further genetic screening and functional assays for a comprehensive range of transcription factors essential for heart development in patients with all types of CHDs would reveal more precise genotype -phenotype correlations, and eventually provide new insights into the molecular mechanisms underlying CHDs.
Conclusions
Genetic and functional analyses of essential cardiac transcription factors in 256 patients with non-syndromic and non-familial CHDs that could not be evaluated using conventional chromosome and/or linkage analysis identified new gene mutations of NKX2.5, GATA4, GATA6, and MEF2C in 6 patients. These mutations may account for approximately 2.3% of OFT defects.
